Consensus treatment recommendations for late-onset Pompe disease
- PMID: 22173792
- PMCID: PMC3534745
- DOI: 10.1002/mus.22329
Consensus treatment recommendations for late-onset Pompe disease
Abstract
Introduction: Pompe disease is a rare, autosomal recessive disorder caused by deficiency of the glycogen-degrading lysosomal enzyme acid alpha-glucosidase. Late-onset Pompe disease is a multisystem condition, with a heterogeneous clinical presentation that mimics other neuromuscular disorders.
Methods: Objective is to propose consensus-based treatment and management recommendations for late-onset Pompe disease.
Methods: A systematic review of the literature by a panel of specialists with expertise in Pompe disease was undertaken.
Conclusions: A multidisciplinary team should be involved to properly treat the pulmonary, neuromuscular, orthopedic, and gastrointestinal elements of late-onset Pompe disease. Presymptomatic patients with subtle objective signs of Pompe disease (and patients symptomatic at diagnosis) should begin treatment with enzyme replacement therapy (ERT) immediately; presymptomatic patients without symptoms or signs should be observed without use of ERT. After 1 year of ERT, patients' condition should be reevaluated to determine whether ERT should be continued.
Copyright © 2011 Wiley Periodicals, Inc.
Figures




Similar articles
-
European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.Eur J Neurol. 2017 Jun;24(6):768-e31. doi: 10.1111/ene.13285. Epub 2017 May 6. Eur J Neurol. 2017. PMID: 28477382
-
Enzyme replacement therapy for infantile-onset Pompe disease.Cochrane Database Syst Rev. 2017 Nov 20;11(11):CD011539. doi: 10.1002/14651858.CD011539.pub2. Cochrane Database Syst Rev. 2017. PMID: 29155436 Free PMC article.
-
The humanistic burden of Pompe disease: are there still unmet needs? A systematic review.BMC Neurol. 2017 Nov 22;17(1):202. doi: 10.1186/s12883-017-0983-2. BMC Neurol. 2017. PMID: 29166883 Free PMC article.
-
Enzyme replacement therapy for late-onset Pompe disease.Cochrane Database Syst Rev. 2023 Dec 12;12(12):CD012993. doi: 10.1002/14651858.CD012993.pub2. Cochrane Database Syst Rev. 2023. PMID: 38084761 Free PMC article.
-
The emerging phenotype of late-onset Pompe disease: A systematic literature review.Mol Genet Metab. 2017 Mar;120(3):163-172. doi: 10.1016/j.ymgme.2016.12.004. Epub 2016 Dec 11. Mol Genet Metab. 2017. PMID: 28185884
Cited by
-
Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe Disease.Int J Mol Sci. 2016 Oct 17;17(10):1735. doi: 10.3390/ijms17101735. Int J Mol Sci. 2016. PMID: 27763517 Free PMC article. Review.
-
Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.J Neurol. 2015;262(4):968-78. doi: 10.1007/s00415-015-7664-0. Epub 2015 Feb 12. J Neurol. 2015. PMID: 25673129
-
Survey on the management of Pompe disease in routine clinical practice in Spain.Orphanet J Rare Dis. 2022 Dec 5;17(1):426. doi: 10.1186/s13023-022-02574-5. Orphanet J Rare Dis. 2022. PMID: 36471448 Free PMC article.
-
Neuromuscular Diseases and Bone.Front Endocrinol (Lausanne). 2019 Nov 22;10:794. doi: 10.3389/fendo.2019.00794. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31824418 Free PMC article. Review.
-
Therapeutic advances in the management of Pompe disease and other metabolic myopathies.Ther Adv Neurol Disord. 2013 Sep;6(5):311-21. doi: 10.1177/1756285613487570. Ther Adv Neurol Disord. 2013. PMID: 23997816 Free PMC article.
References
-
- Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2:i–iv. 1–88. - PubMed
-
- Pompe JC. Over idioptische hypertrophie van het hart. Ned Tidschr Geneeskd. 1932;76:304–311.
-
- Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr. 2004;144(suppl):S35–S43. - PubMed
-
- Cori GT. Biochemical aspects of glycogen deposition disease. Mod Probl Paediat. 1957;3:344–358. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical